Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis
Open Access
- 1 October 2015
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 149 (4), 971-980.e1
- https://doi.org/10.1053/j.gastro.2015.07.001
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Sofosbuvir for Previously Untreated Chronic Hepatitis C InfectionNew England Journal of Medicine, 2013
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2011
- Telaprevir for Retreatment of HCV InfectionNew England Journal of Medicine, 2011
- Boceprevir for Untreated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A proteaseXenobiotica, 2010
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C InfectionNew England Journal of Medicine, 2009
- Diagnosis, management, and treatment of hepatitis C†Hepatology, 2004
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and CirrhosisNew England Journal of Medicine, 2000
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis CNew England Journal of Medicine, 2000